Adam Kotkiewicz, DO
Hematology & Oncology · Palm Springs, FLNPI 1356491179
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (51.0%), food and beverage and consulting fees — rather than concentrated in one kind of arrangement. 19 manufacturers reported payments, led by Avyxa Pharma, LLC at 54.7% of the total. 2025 is the largest year on record at $3,113, more than ten times the $268 reported in 2019. That places this record below the midpoint for hematology & oncology clinicians in FL, where the typical reported total is $3,884.
Across 43 payments — averaging $125.46 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Avyxa Pharma, LLC$3K
- AstraZeneca$1K
- Daiichi Sankyo Inc.$772
- Sirtex Medical Inc$143
- Novartis$88
- Tempus AI, Inc$75
- plus $263 from 13 others
Across 10 payments — averaging $1303.35 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Incyte Corporation$13K
What the payments were for
- Consulting fees$92517%
- Speaking & faculty fees$2,75051%
- Travel & lodging$68213%
- Food & beverage$1,03819%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Avyxa Pharma, LLC | 4 | $2,949 |
| AstraZeneca | 12 | $1,106 |
| Daiichi Sankyo Inc. | 3 | $772 |
| Sirtex Medical Inc | 1 | $143 |
| Novartis | 5 | $88 |
| Tempus AI, Inc | 1 | $75 |
| Johnson & Johnson | 3 | $46 |
| Genentech USA, Inc. | 2 | $33 |
| Gilead(2 entities) | 2 | $32 |
| Array Biopharma Inc | 1 | $21 |
| Astellas Pharma US Inc | 1 | $18 |
| Sanofi | 1 | $16 |
| Bayer | 1 | $16 |
| Kyowa Kirin, Inc. | 1 | $16 |
| Adaptive Biotechnologies Corporation | 1 | $14 |
| Pharmacyclics LLC, An Abbvie Company | 1 | $14 |
| Pfizer | 1 | $13 |
| Rigel Pharmaceuticals, Inc. | 1 | $13 |
| E.r. Squibb & Sons, L.L.C. | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- CALQUENCE$525
- IMFINZI$400
- SIR-Spheres Microspheres$143
How this compares
$5,395 in reported general payments places this provider in the 50th percentile of 694 hematology & oncology providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Lenalidomide | 13 | $191,180 |
| BrukinsaZanubrutinib | 13 | $174,064 |
| Abiraterone Acetate | 41 | $60,780 |
| OrgovyxRelugolix | 12 | $30,722 |
| EliquisApixaban | 12 | $8,401 |
| Hydroxyurea | 34 | $584 |
| Prednisone | 100 | $403 |
| Prochlorperazine Maleate | 19 | $229 |
| Acyclovir | 11 | $169 |
| Ondansetron Hcl | 18 | $112 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $13 | $8,40112 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 50th percentile of 694 hematology & oncology providers in Florida.
Other hematology & oncology in Palm Springs
- Martin DietrichRockledge$6.2M
- Mark SocinskiOrlando$2.4M
- Tarek MekhailOrlando$2.2M
- Edgardo SantosFort Lauderdale$2M
- Daniel LandauOrlando$1.8M
- Wassim McHaylehAltamonte Springs$1.5M
- Edith PerezJacksonville$1.1M
- Steven FeinMiami$1M
- Vamsidhar VelchetiJacksonville$966K
- Shahram MoriOrlando$952K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.